Aytu BioPharma (NASDAQ:AYTU – Get Free Report) and Milestone Pharmaceuticals (NASDAQ:MIST – Get Free Report) are both small-cap healthcare companies, but which is the better stock? We will contrast the two businesses based on the strength of their profitability, analyst recommendations, institutional ownership, earnings, risk, dividends and valuation.
Profitability
This table compares Aytu BioPharma and Milestone Pharmaceuticals’ net margins, return on equity and return on assets.
| Net Margins | Return on Equity | Return on Assets | |
| Aytu BioPharma | -24.76% | -56.54% | -13.14% |
| Milestone Pharmaceuticals | N/A | -288.33% | -58.27% |
Volatility and Risk
Aytu BioPharma has a beta of 0.26, suggesting that its share price is 74% less volatile than the S&P 500. Comparatively, Milestone Pharmaceuticals has a beta of 0.98, suggesting that its share price is 2% less volatile than the S&P 500.
Institutional and Insider Ownership
Analyst Recommendations
This is a breakdown of recent ratings and target prices for Aytu BioPharma and Milestone Pharmaceuticals, as provided by MarketBeat.com.
| Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score | |
| Aytu BioPharma | 1 | 1 | 2 | 0 | 2.25 |
| Milestone Pharmaceuticals | 1 | 1 | 4 | 1 | 2.71 |
Aytu BioPharma currently has a consensus target price of $14.50, indicating a potential upside of 535.96%. Milestone Pharmaceuticals has a consensus target price of $6.40, indicating a potential upside of 711.77%. Given Milestone Pharmaceuticals’ stronger consensus rating and higher probable upside, analysts clearly believe Milestone Pharmaceuticals is more favorable than Aytu BioPharma.
Earnings and Valuation
This table compares Aytu BioPharma and Milestone Pharmaceuticals”s gross revenue, earnings per share (EPS) and valuation.
| Gross Revenue | Price/Sales Ratio | Net Income | Earnings Per Share | Price/Earnings Ratio | |
| Aytu BioPharma | $57.57 million | 0.43 | -$13.56 million | ($1.66) | -1.37 |
| Milestone Pharmaceuticals | $2.34 million | 41.89 | -$63.06 million | ($0.69) | -1.14 |
Aytu BioPharma has higher revenue and earnings than Milestone Pharmaceuticals. Aytu BioPharma is trading at a lower price-to-earnings ratio than Milestone Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.
Summary
Milestone Pharmaceuticals beats Aytu BioPharma on 11 of the 15 factors compared between the two stocks.
About Aytu BioPharma
Aytu Biopharma, Inc. is a specialty pharmaceutical company, which engages in identifying, acquiring, and commercializing novel products. It operates through the Rx and Consumer Health segments. The RX segment consists of various prescription pharmaceutical products sold through third parties. The Consumer Health segment includes various consumer health products sold directly to consumers. Its products include Adzenys ER, Adzenys XR-ODT, Cotempla XR-ODT, Karbinal ER, Poly-Vi-Flor, Tri-Vi-Flor, Generic Tussionex, Tuzistra XR, and ZolpiMist. The company was founded on August 9, 2002 and is headquartered in Englewood, CO.
About Milestone Pharmaceuticals
Milestone Pharmaceuticals Inc., a biopharmaceutical company, focuses on the development and commercialization of cardiovascular medicines. The company's lead product candidate is etripamil, a novel and potent calcium channel blocker, which is in Phase III clinical trial for the treatment of paroxysmal supraventricular tachycardia in the United States and Canada; and Phase II clinical trial for the treatment of atrial fibrillation and rapid ventricular rate. It has a license and collaboration agreement with Ji Xing Pharmaceuticals to develop and commercialize etripamil prophylactic and therapeutic uses in humans, as well as with the Montreal Heart Institute, the WCN network, and other research centers. The company was incorporated in 2003 and is headquartered in Montréal, Canada.
Receive News & Ratings for Aytu BioPharma Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Aytu BioPharma and related companies with MarketBeat.com's FREE daily email newsletter.
